Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. Chief Business Officer Pierre Kyme reported a small tax-related share disposition on common stock. On March 14, 2026, 1,030 shares were withheld at $10.54 per share to satisfy income tax and withholding obligations tied to restricted stock unit settlement. Following this transaction, Kyme directly holds 9,461 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyme Pierre

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		F		1,030(1)	D	$10.54	9,461	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.

	/s/ Pierre Kyme	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Armata Pharmaceuticals (ARMP) disclose in this Form 4 filing?

Armata Pharmaceuticals reported a tax-related share disposition by Chief Business Officer Pierre Kyme. The company withheld 1,030 common shares to cover income tax and withholding obligations arising from the net settlement of restricted stock units on March 14, 2026.

How many Armata Pharmaceuticals (ARMP) shares were affected in Pierre Kyme’s transaction?

The transaction involved 1,030 shares of Armata Pharmaceuticals common stock. These shares were not sold in the open market; they were withheld by the company to satisfy income tax and withholding remittance obligations related to restricted stock unit settlement.

Was the Armata Pharmaceuticals (ARMP) Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. The 1,030 shares were withheld by Armata Pharmaceuticals to cover income tax and withholding obligations for net-settled restricted stock units, classified as a tax-withholding disposition under transaction code F.

How many Armata Pharmaceuticals (ARMP) shares does Pierre Kyme hold after this filing?

After the tax-withholding transaction, Pierre Kyme directly holds 9,461 shares of Armata Pharmaceuticals common stock. This figure reflects his position following the company’s withholding of 1,030 shares to satisfy income tax and related remittance obligations tied to restricted stock units.

What does transaction code F mean in the Armata Pharmaceuticals (ARMP) Form 4?

Transaction code F indicates shares were used to pay an exercise price or tax liability. In this case, 1,030 Armata Pharmaceuticals shares were withheld by the company to cover income tax and withholding remittance obligations from the net settlement of restricted stock units.

Who is the insider involved in this Armata Pharmaceuticals (ARMP) Form 4?

The insider is Pierre Kyme, Chief Business Officer of Armata Pharmaceuticals. He reported a tax-withholding disposition where 1,030 common shares were withheld by the company for income tax and withholding obligations related to restricted stock unit settlement, leaving him with 9,461 shares.